TY  - JOUR
A1  - Jeanclos, Elisabeth
A1  - Schlötzer, Jan
A1  - Hadamek, Kerstin
A1  - Yuan-Chen, Natalia
A1  - Alwahsh, Mohammad
A1  - Hollmann, Robert
A1  - Fratz, Stefanie
A1  - Yesilyurt-Gerhards, Dilan
A1  - Frankenbach, Tina
A1  - Engelmann, Daria
A1  - Keller, Angelika
A1  - Kaestner, Alexandra
A1  - Schmitz, Werner
A1  - Neuenschwander, Martin
A1  - Hergenröder, Roland
A1  - Sotriffer, Christoph
A1  - von Kries, Jens Peter
A1  - Schindelin, Hermann
A1  - Gohla, Antje
T1  - Glycolytic flux control by drugging phosphoglycolate phosphatase
JF  - Nature Communications
N2  - Targeting the intrinsic metabolism of immune or tumor cells is a therapeutic strategy in autoimmunity, chronic inflammation or cancer. Metabolite repair enzymes may represent an alternative target class for selective metabolic inhibition, but pharmacological tools to test this concept are needed. Here, we demonstrate that phosphoglycolate phosphatase (PGP), a prototypical metabolite repair enzyme in glycolysis, is a pharmacologically actionable target. Using a combination of small molecule screening, protein crystallography, molecular dynamics simulations and NMR metabolomics, we discover and analyze a compound (CP1) that inhibits PGP with high selectivity and submicromolar potency. CP1 locks the phosphatase in a catalytically inactive conformation, dampens glycolytic flux, and phenocopies effects of cellular PGP-deficiency. This study provides key insights into effective and precise PGP targeting, at the same time validating an allosteric approach to control glycolysis that could advance discoveries of innovative therapeutic candidates.
KW  - phosphoglycolate phosphatase
KW  - glycolytic flux control
KW  - intrinsic metabolism
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300928
VL  - 13
IS  - 1
ER  - 
TY  - JOUR
A1  - Ohlebusch, Barbara
A1  - Borst, Angela
A1  - Frankenbach, Tina
A1  - Klopocki, Eva
A1  - Jakob, Franz
A1  - Liedtke, Daniel
A1  - Graser, Stephanie
T1  - Investigation of alpl expression and Tnap-activity in zebrafish implies conserved functions during skeletal and neuronal development
JF  - Scientific Reports
N2  - Hypophosphatasia (HPP) is a rare genetic disease with diverse symptoms and a heterogeneous severity of onset with underlying mutations in the ALPL gene encoding the ectoenzyme Tissue-nonspecific alkaline phosphatase (TNAP). Considering the establishment of zebrafish (Danio rerio) as a new model organism for HPP, the aim of the study was the spatial and temporal analysis of alpl expression in embryos and adult brains. Additionally, we determined functional consequences of Tnap inhibition on neural and skeletal development in zebrafish. We show that expression of alpl is present during embryonic stages and in adult neuronal tissues. Analyses of enzyme function reveal zones of pronounced Tnap-activity within the telencephalon and the mesencephalon. Treatment of zebrafish embryos with chemical Tnap inhibitors followed by axonal and cartilage/mineralized tissue staining imply functional consequences of Tnap deficiency on neuronal and skeletal development. Based on the results from neuronal and skeletal tissue analyses, which demonstrate an evolutionary conserved role of this enzyme, we consider zebrafish as a promising species for modeling HPP in order to discover new potential therapy strategies in the long-term.
KW  - nonspecific alkaline-phosphae
KW  - in situ hybridization
KW  - hypophosphatasia
KW  - promotes
KW  - model
KW  - neurotransmission
KW  - differentiation
KW  - mineraliztion
KW  - metabolism
KW  - vertebrate
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-230024
VL  - 10
ER  -